ArticleFrontiers in oncology2026
Novel use of peak optimized particle therapy for the delivery of three-dimensional spatially fractionated radiotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spatially fractionated radiotherapy (SFRT) has been delivered safely and effectively mostly utilizing beamlets of megavoltage photons in recent years. Particle therapy offers the promise of improved dose distributions with less exposure of surrounding normal tissues. However, most efforts have focused on mimicking the beamlets of traditional SFRT two-dimensional therapy (also known as GRID), potentially sacrificing advantages that could be achieved with scanned particle beams. We, herein, lay out the rationale for and execution of a novel pencil beam scanning proton therapy technique for SFRT that prioritizes pristine Bragg peak delivery in an interleaved and rotated three-dimensional SFRT (LATTICE) format. We propose that this patented (US11478665B2) technique optimizes particle SFRT therapy radiobiologic effect, minimizes normal tissue and superficial dose, and allows for alternative SFRT applications across a course of therapy. This technique lends itself to further exploration in delivery techniques, fractionation, and ultra-high dose rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.